Mitochondrial Medicine - Therapeutic Development
2024-03-18 - 2024-03-20 | MA
In mid-March, Abliva will attend the 8th edition of Mitochondrial Medicine – Therapeutic Development in Hinxton, UK.
This annual scientific meeting is focused on mitochondrial disorders and the search for novel effective therapies.
Abliva’s CMO, Maguns Hansson, will join the panel discussion Challenges and opportunities in clinical trials: perspectives
from pharma and funders, where representatives from other companies in the field as well as academic and clinical experts also participate.
Follow the link below to learn more.

Kempen Life Sciences Conference
2024-04-16 - 2024-04-17 | MA
In mid-April, Abliva will participate at Kempen Life Sciences Conference in Amsterdam, The Netherlands.
For more information, please click the link below.

Bio€quity Europe
2024-05-12 - 2024-05-14 | Kursaal Elkargunea Center, Zurriola Hiribidea, 1, San Sebastián, 20002, Spain
In mid-May, Abliva will travel to the Bio€quity Europe meeting in San Sebastán, Spain.
“For more than 20 years, Bio€quity Europe has been where CEOs and investors gather to network, partner, and debate critical issues facing the biotech industry.”
Abliva’s CEO, Ellen Donnelly, will, together with the company’s CMO, Magnus Hansson, be networking and presenting the company during the event.
Follow the link below to learn more.

Virtual KOL event on KL1333
2024-05-21 16:00 - 17:00 (Europe/Stockholm) | MA
Join Abliva for a virtual KOL event featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently no approved medicines for the systemic disease.
The event will focus on Abliva’s lead program, KL1333, which has shown clinically meaningful, early signals of efficacy in mitochondrial disease patients. This novel therapeutic approach modulates the underlying pathophysiology in mitochondrial disease. KL1333 is currently being evaluated in the pivotal Phase 2 FALCON trial, with interim analysis expected mid-year 2024. KL1333 has Orphan Drug Designation (ODD) in both Europe and the U.S. and Fast Track designation in the U.S.
Registration information
Register here: https://lifescievents.com/event/abliva/
A live question and answer session will follow the formal presentation. Ask your question to: questions@lifesciadvisors.com.
You are required to register in advance for the webcast. For those who are unable to attend live, a replay will be available via the link below.

BIO International
2024-06-03 - 2024-06-06 | San Diego, San Diego, CA, United States
In early June, Abliva’s CEO, Ellen Donnelly, travels to San Diego to attend BIO International 2024.
Follow the link below for more information.

Mito Med 2024
2024-06-26 - 2024-06-29 | Cleveland, Ohio, Cleveland, OH, United States
In late June, Abliva will attend the US patient organization UMDF’s Mitochondrial Medicine Conference in Cleveland, Ohio.
“Each year, UMDF’s Mitochondrial Medicine Conference brings together the best minds in mitochondrial medicine and the patients we serve. With over 700 attendees representing almost every state in the U.S. and more than 15 different countries, the Conference is recognized as the world’s preeminent event for mitochondrial disease.”
Click the link below for more information.

Nordic Life Science Days
2024-09-18 - 2024-09-19 | Malmömässan, Mässgatan 6, Malmö, 215 32, Sweden
In September, Abliva will attend the Nordic Life Science Days (NLS days) in Malmö, Sweden.
Ablia’s CEO, Ellen Donnelly, will be presenting the company at 11:00 a.m. CET on September 18, in the session Biotechnology.
Follow the link below for more information.

Mitocon's Mitochondrial Disease Conference
2024-10-25 - 2024-10-27 | BW Plus Hotel Galileo, Via Venezia 30, Padova, Italy
In late October, Abliva will attend the 14th Mitochondrial Disease Conference, this year in Padua (IT), organized by the Italian patient organization Mitocon.
Abliva’s CMO, Magnus Hansson will attend the session: Roundtable with Pharmaceutical Industries and Regulatory Authorities.
Read more by following the link below.

BIO-Europe
2024-11-04 - 2024-11-06 | Stockholm, Stockholm, Sweden
In early November, Abliva’s CEO, Ellen Donnelly, will attend the BIO-Europe meeting in Stockholm, Sweden.
On Monday, November 4, Ellen will be presenting the company at 4:30 p.m. CET.
Follow the link below for further details.

CNS Summit 2024
2024-11-10 - 2024-11-13 | Encore Boston Harbor, Boston, MA, United States
Abliva will attend the CNS Summit 2024, taking place November 10-13 at Encore Boston Harbor.
The company’s CEO, Ellen Donnelly, has organized and will join the spotlight panel discussion: Medicines for Mito: Developing Medicines for Mitochondrial Dysfunction Spotlight Session, on November 11, at 1:00 p.m. ET, featuring representatives from Stealth-, Tisento- and Saol Therapeutics.
Follow the link below for further details.

Investival Showcase
2024-11-18 | Tobacco Dock, Wapping Lane, London, E1W 2SF, United Kingdom
In mid-November, Abliva will attend LSX’s Investival Showcase in London, UK.
Abliva’s CEO, Ellen Donnelly, will be presenting the company at 11:30 a.m. GMT.
The Investival Showcase is a Biotech, Healthtech, and Medtech Networking & Pitching Event.
Follow the link below for more details.

BioStock Life Science Summit
2024-11-19 - 2024-11-21 | Medicon Village, Scheeletorget 1, Lund, Sweden
In late November, Abliva will participate in BioStock’s Life Science Summit in Lund, Sweden.
CMO, Magnus Hansson, will be presenting the company at 15:10 CET on November 21.
For more details on the event, follow the link below.
